Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Wake Forest University Health Sciences
With
National Cancer Institute (NCI)
OBJECTIVES:
* Optimize and standardize the in vitro cell kill assay using human white blood cells and human cancer cell lines from patients with metastatic cancer and from healthy participants.
* Determine the results of the in vitro cell kill assay in patients with metastatic cancer and in healthy participants with no history of cancer.
OUTLINE: This is a pilot study.
Peripheral blood is obtained from healthy participants and from cancer patients. Tissue is collected from archived samples. White blood cells are obtained from tissue and blood samples and are assessed by the in vitro cell kill assay.
PROJECTED ACCRUAL: A total of 24 patients and 24 healthy participants will be accrued for this study.
Age
0–120
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Meets 1 of the following criteria:
Diagnosis of metastatic cancer including, but not limited to, any of the following:
* Stage IV non-small cell lung cancer
* Extensive-stage small cell lung cancer
* Metastatic testicular cancer
* Stage IV breast carcinoma
* Stage III or IV ovarian carcinoma
* Stage IV endometrial carcinoma
* Stage IV prostate carcinoma
* Stage IV colorectal or pancreatic cancer
* Stage IV renal cancer
* Stage III or IV non-Hodgkin's lymphoma
* Stage IV bladder cancer
* Stage III multiple myeloma (Salmon-Durie staging)
* Metastatic melanoma
* Metastatic sarcoma
Healthy participant, meeting the following criteria:
* No prior cancer
* Over 50 years of age
You may not be if
Serious medical or psychiatric condition that would preclude study compliance
Chemotherapy or radiotherapy within the past 3 months (patient)
Prior immunosuppressive therapy or radiotherapy for any disease (healthy participant)
Clareo Health | Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
